Literature DB >> 11287095

Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors.

T Kannoa1, A Kanatani, S L Keen, S Arai-Otsuki, Y Haga, T Iwama, A Ishihara, A Sakuraba, H Iwaasa, M Hirose, H Morishima, T Fukami, M Ihara.   

Abstract

The peptidic Y1 antagonist 1229U91 and the non-peptidic antagonist J-104870 have high binding affinities for the human Y1 receptor. These Y1 antagonists show anorexigenic effects on NPY-induced feeding in rats, although they have completely different structures and molecular sizes. To identify the binding sites of these ligands, we substituted amino acid residues of the human Y1 receptor with alanine and examined the abilities of the mutant receptors to bind the radio-labeled ligands. Alanine substitutions, F98A, D104A, T125A, D200A, D205A, L215A, Q219A, L279A, F282A, F286A, W288A and H298A, in the human Y1 receptor lost their affinity for the peptide agonist PYY, but not for 1229U91 and J-104870, while L303A and F173A lost affinity for 1229U91 and J-104870, respectively. N283A retained its affinity for 1229U91, but not for PYY and J-104870. Y47A and N299A retained their affinity for J-104870, but not for PYY and 1229U91. W163A and D287A showed no affinity for any of the three ligands. Taken together, these data indicate that the binding sites of 1229U91 are widely located in the shallow region of the transmembrane (TM) domain of the receptor, especially TM1, TM6 and TM7. In contrast, J-104870 recognized the pocket formed by TM4, TM5 and TM6, based on the molecular modeling of the Y1 receptor and J-104870 complex. In conclusion, 1229U91 and J-104870 have high affinities for Y1 receptors using basically different binding sites. D287 of the common binding site in the TM6 domain could be crucial for the binding of Y1 antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287095     DOI: 10.1016/s0196-9781(01)00350-3

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

1.  Re-evaluation of receptor-ligand interactions of the human neuropeptide Y receptor Y1: a site-directed mutagenesis study.

Authors:  Paula Sjödin; Sara K S Holmberg; Helena Akerberg; Magnus M Berglund; Nina Mohell; Dan Larhammar
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.

Authors:  Shuanghua Hu; Yazhong Huang; Milind Deshpande; Guanglin Luo; Marc A Bruce; Ling Chen; Gail Mattson; Lawrence G Iben; Jie Zhang; John W Russell; Wendy J Clarke; John B Hogan; Astrid Ortiz; Oliver Flint; Andrew Henwood; Qi Gao; Ildiko Antal-Zimanyi; Graham S Poindexter
Journal:  ACS Med Chem Lett       Date:  2012-01-04       Impact factor: 4.345

3.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

4.  Pancreatic polypeptide is recognized by two hydrophobic domains of the human Y4 receptor binding pocket.

Authors:  Xavier Pedragosa-Badia; Gregory R Sliwoski; Elizabeth Dong Nguyen; Diana Lindner; Jan Stichel; Kristian W Kaufmann; Jens Meiler; Annette G Beck-Sickinger
Journal:  J Biol Chem       Date:  2013-12-27       Impact factor: 5.157

5.  Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors.

Authors:  Tingting Tang; Qiuxiang Tan; Shuo Han; Anne Diemar; Kristin Löbner; Hongyu Wang; Corinna Schüß; Victoria Behr; Karin Mörl; Mu Wang; Xiaojing Chu; Cuiying Yi; Max Keller; Jacob Kofoed; Steffen Reedtz-Runge; Anette Kaiser; Annette G Beck-Sickinger; Qiang Zhao; Beili Wu
Journal:  Sci Adv       Date:  2022-05-04       Impact factor: 14.957

6.  Neuropeptide Y receptors: how to get subtype selectivity.

Authors:  Xavier Pedragosa-Badia; Jan Stichel; Annette G Beck-Sickinger
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-04       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.